

香港聯合交易所有限公司  
(香港交易及結算所有限公司全資附屬公司)

THE STOCK EXCHANGE OF HONG KONG LIMITED  
(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

## 通告 CIRCULAR

香港聯合交易所有限公司竭力確保其提供之資料準確可靠，惟不保證該等資料絕對正確，亦不對由於任何資料不確或遺漏所引之損失或損害負上責任(不論是民事侵權行為責任或合約責任或其他)。

The Stock Exchange of Hong Kong Limited endeavours to ensure the accuracy and reliability of the information provided, but does not guarantee its accuracy and accepts no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions

### FOR REFERENCE ONLY

Subject : Display of Previous Closing Price of Sihuan Pharmaceutical Holdings Group Ltd. (stock code 460) on OTP-C for the Preferential Offering of the H shares of Xuanzhu Biopharmaceutical Co., Ltd. on Ex-Entitlement Date, 16 September 2025

Enquiry Tel : Mr. Leo Cheung (Tel: 2840 3450) or Ms. Cynthia Chiu (Tel: 2840 3076)

Sihuan Pharmaceutical Holdings Group Ltd. ("Sihuan Pharmaceutical") announced a spin-off proposal for a separate listing of Xuanzhu Biopharmaceutical Co., Ltd. ("Xuanzhu Biopharmaceutical") (the "Proposed Spin-Off"). Qualifying shareholders of Sihuan Pharmaceutical will be entitled to apply for the H shares of Xuanzhu Biopharmaceutical on an assured basis under the Preferential Offering (the "Preferential Offering"). According to the timetable for the Preferential Offering, Sihuan Pharmaceutical's shares (stock code 460) will be marked "ex-entitlement" on 16 September 2025, the Ex-Entitlement Date.

Given that the exact value of the H shares of Xuanzhu Biopharmaceutical is not known, the Exchange will display "N/A" in the "PRV CLOSE" field of Sihuan Pharmaceutical's OTP-C stock page on 16 September 2025, the Ex-Entitlement Date in accordance with the OTP-C standard practice. The unadjusted previous closing price will be displayed in the free text field.

Shareholders, investors and market participants should read the announcements issued by Sihuan Pharmaceutical in full including the terms and conditions of the Proposed Spin-Off and the Preferential Offering in dealing with Sihuan Pharmaceutical's shares. If they are in doubt, they should consult their professional adviser(s).

Charles Woo  
Vice President  
Post Trade  
Operations Division